Dr Reddy's Laboratories Total Long Term Liabilities 2010-2024 | RDY

Dr Reddy's Laboratories total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
  • Dr Reddy's Laboratories total long term liabilities for the quarter ending September 30, 2024 were $0.327B, a 177.12% increase year-over-year.
  • Dr Reddy's Laboratories total long term liabilities for 2024 were $0.132B, a 112.9% increase from 2023.
  • Dr Reddy's Laboratories total long term liabilities for 2023 were $0.062B, a 43.64% decline from 2022.
  • Dr Reddy's Laboratories total long term liabilities for 2022 were $0.11B, a 11.29% decline from 2021.
Dr Reddy's Laboratories Annual Total Long Term Liabilities
(Millions of US $)
2024 $132
2023 $62
2022 $110
2021 $124
2020 $59
2019 $369
2018 $452
2017 $167
2016 $222
2015 $313
2014 $424
2013 $287
2012 $365
2011 $179
2010 $186
2009 $100
Dr Reddy's Laboratories Quarterly Total Long Term Liabilities
(Millions of US $)
2024-09-30 $327
2024-06-30 $180
2024-03-31 $132
2023-12-31 $137
2023-09-30 $118
2023-06-30 $110
2023-03-31 $62
2022-12-31 $57
2022-09-30 $59
2022-06-30 $61
2022-03-31 $110
2021-12-31 $118
2021-09-30 $117
2021-06-30 $116
2021-03-31 $124
2020-12-31 $124
2020-09-30 $130
2020-06-30 $128
2020-03-31 $59
2019-12-31 $63
2019-09-30 $267
2019-06-30 $289
2019-03-31 $369
2018-12-31 $409
2018-09-30 $434
2018-06-30 $441
2018-03-31 $452
2017-12-31 $456
2017-09-30 $458
2017-06-30 $456
2017-03-31 $167
2016-12-31 $160
2016-09-30 $236
2016-06-30 $210
2016-03-31 $222
2015-12-31 $241
2015-09-30 $237
2015-06-30 $278
2015-03-31 $313
2014-12-31 $331
2014-09-30 $365
2014-06-30 $398
2014-03-31 $424
2013-12-31 $427
2013-09-30 $448
2013-06-30 $276
2013-03-31 $287
2012-12-31 $375
2012-09-30 $375
2012-06-30 $352
2012-03-31 $365
2011-12-31 $357
2011-09-30 $167
2011-06-30 $184
2011-03-31 $179
2010-12-31 $63
2010-09-30 $110
2010-06-30 $150
2010-03-31 $186
2009-12-31 $219
2009-09-30 $269
2009-06-30 $291
2009-03-31 $299
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $11.677B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.350B 6.35
BridgeBio Pharma (BBIO) United States $4.392B 0.00
Bausch Health Cos (BHC) Canada $3.009B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.142B 12.88
Supernus Pharmaceuticals (SUPN) United States $1.978B 26.93
Taysha Gene Therapies (TSHA) United States $0.447B 31.14
Personalis (PSNL) United States $0.239B 0.00
Assembly Biosciences (ASMB) United States $0.094B 0.00
Sol-Gel Technologies (SLGL) Israel $0.013B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00